Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AP402 |
| Synonyms | |
| Therapy Description |
AP402 is a bispecific antibody targeting an extracellular domain truncated form of ERBB2 (HER2) (p95HER2) and CD137, which potentially induces antibody-dependent cellular cytotoxicity in tumor cells expressing p95HER2 and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 6016). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AP402 | AP-402|AP 402 | HER2 (ERBB2) Antibody 79 | AP402 is a bispecific antibody targeting an extracellular domain truncated form of ERBB2 (HER2) (p95HER2) and CD137, which potentially induces antibody-dependent cellular cytotoxicity in tumor cells expressing p95HER2 and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 6016). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06669975 | Phase Ib/II | AP402 | A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors | Recruiting | AUS | 0 |